Bach Ardalan, Seth A Spector, Alan S Livingstone, Dido Franceschi, Dmitry Mezentsev, Mayra Lima, Carol P Bowen-Wells, Lynne Sparling, Eli Avisar, Michelle Sapp, Joyce Rios, Gail Walker, Parvin Ganjei-Azar
BACKGROUND: A phase II trial to evaluate neoadjuvant (NAD), surgery and adjuvant (AD) combination chemotherapy without radiation therapy (RT) for patients with esophageal adenocarcinoma staged with endoscopic ultrasound and CT as T3N1 was carried out. METHODS: Thirty-three eligible patients were enrolled. NAD therapy was administered in two 49-day cycles and included cisplatin, floxuridine, paclitaxel and leucovorin. Esophageal resection was performed followed by AD therapy...
August 2007: Japanese Journal of Clinical Oncology